Principal Financial Group
HBIO icon

Principal Financial Group’s Harvard Bioscience HBIO Stock Holding History

Principal Financial Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,892
Closed -$117K – 2562
2022
Q1 		$117K Sell
1,892
-962
-34% -$56.9K ﹤0.01% 2413
2021
Q4 		$201K Buy
+2,854
New +$203K ﹤0.01% 2363
2013
Q3 		– Sell
-1,390
Closed -$50K – 2277
2013
Q2 		$50K Buy
+1,390
New +$53.2K ﹤0.01% 2245

Other funds holding HBIO

HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group's HBIO Position: Q2 2022 in Review

Principal Financial Group sold out of Harvard Bioscience (HBIO) in Q2 2022, closing a stake of 1,892 shares — an estimated $117K sold.

Principal Financial Group first reported a position in HBIO in Q2 2013 and held it in 3 quarters. The position peaked at $201K in Q4 2021. 90 funds tracked by Wall St. Rank hold HBIO as of Q2 2022.

  • Principal Financial Group reported no remaining Harvard Bioscience position as of Q2 2022 after selling out during the quarter.
  • Principal Financial Group sold 1,892 Harvard Bioscience shares in Q2 2022, an estimated $117K.
  • Principal Financial Group first reported a position in Harvard Bioscience in Q2 2013 and held it in 3 quarters.
  • Principal Financial Group's Harvard Bioscience position peaked at $201K in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2022.

Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.